Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Rang in Aktien
#3772
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Aktienkurs
$4.87
Marktkapitalisierung
$4.36B
Veränderung (1 Tag)
-5.47%
Veränderung (1 Jahr)
-15.62%
Land
CN
Handel Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Kategorie
Healthcare
P/S-Verhältnis für Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
P/S-Verhältnis zum October 2026 TTM: 6.59
Laut den neuesten Finanzberichten und dem Aktienkurs von Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 6.59. Am Ende des Jahres 2024 lag das P/S-Verhältnis bei 11.09.
P/S-Verlauf für Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd von 2006 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 6.59 | 9.03% |
| 2025 | 6.04 | -45.55% |
| 2024 | 11.09 | -17.86% |
| 2023 | 13.50 | 42.44% |
| 2022 | 9.48 | -21.14% |
| 2021 | 12.02 | -45.65% |
| 2020 | 22.12 | -9.73% |
| 2019 | 24.50 | 0.76% |
| 2018 | 24.32 | -3.03% |
| 2017 | 25.08 | -11.90% |
| 2016 | 28.47 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | -100.00% |
| 2012 | 46.19 | -21.47% |
| 2011 | 58.81 | -21.40% |
| 2010 | 74.82 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| 10.72 | 62.80% |
US
|
|
| 41.70 | 533.21% |
US
|
|
| 4.19 | -36.36% |
AU
|
|
| 5.80 | -12.00% |
BE
|
|
| 10.44 | 58.57% |
NL
|
